

Datasheet: MCA1781R

BATCH NUMBER 147759

Description:	MOUSE ANTI CANINE CD21
Specificity:	CD21
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	CA2.1D6
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/100
Immunohistology - Frozen (1)	▪			
Immunohistology - Paraffin		▪		
ELISA			▪	
Immunoprecipitation	▪			
Western Blotting			▪	

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

(1)The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.

Target Species

Dog

Species Cross Reactivity

Reacts with: Horse, Cat, Raccoon

N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

Product Form	Purified IgG - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
RRID	AB_323665
Specificity	<p>Mouse anti Canine CD21 antibody, clone CA2.1D6 recognizes canine CD21, also known as Complement receptor type 2. CD21 is a cell surface antigen expressed by canine B lymphocytes.</p> <p>The antigen recognized may be the canine homologue of human CD21, but this has not been fully confirmed.</p> <p>Mouse anti Canine CD21 antibody , clone CA2.1D6 also recognizes the CD21 antigen in Felids. Expression in cats is analogous to that seen in dogs with strong expression on lymphocytes, in a manner mutually exclusive with expression of CD4 or CD8. Mouse anti Canine CD21 antibody, clone CA2.1D6 immunoprecipitates a ~145 kDa protein from feline lymphocytes, similar to the protein immunoprecipitated by the antibody from canine lymphocytes (Dean et al. 1996).</p>
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells or 100ul whole blood.
References	<ol style="list-style-type: none"> Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens. 43 (3): 137-54. Brodersen, R. et al. (1998) Analysis of the immunological cross reactivities of 213 well characterized monoclonal antibodies with specificities against various leucocyte surface antigens of human and 11 animal species. Vet Immunol Immunopathol. 64 (1): 1-13. Dean, G.A. et al. (1996) Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol. 70 (8): 5165-9. Faldyna, M. et al. (2004) Lymphocyte subsets in synovial fluid from clinically healthy joints of dogs. Acta Vet. Brno 73: 73-8. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. Cell Immunol. 263: 88-98. Huang, Y.C. et al. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J Leukoc Biol. 84: 1501-10. Mortarino, M. et al. (2009) ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases. Vet Immunol Immunopathol. 128: 395-401. Reggeti, F. et al. (2008) CD134 and CXCR4 expression corresponds to feline

- immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells. [J Gen Virol. 89: 277-87.](#)
9. Wang, Y.S. *et al.* (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation. [Can J Vet Res. 71: 165-74.](#)
 10. Lankford, S. *et al.* (2008) Cloning of feline FOXP3 and detection of expression in CD4+CD25+ regulatory T cells. [Vet Immunol Immunopathol. 122: 159-66.](#)
 11. Araujo, M.S. *et al.* (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. [Vet Immunol Immunopathol. 141: 64-75.](#)
 12. Estrela-Lima, A. *et al.* (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. [BMC Cancer. 10: 256.](#)
 13. Horn, P.A. *et al.* (2004) Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. [Blood. 103: 3710-6.](#)
 14. Hsiao, Y.W. *et al.* (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. [J Immunol. 172: 1508-14.](#)
 15. Jubala, C.M. *et al.* (2005) CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. [Vet Pathol. 42: 468-76.](#)
 16. Gaurnier-Hausser, A. *et al.* (2011) NEMO-Binding Domain Peptide Inhibits Constitutive NF- κ B Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma. [Clin Cancer Res. 17: 4661-71.](#)
 17. Maiolini, A. *et al.* (2012) Toll-like receptors 4 and 9 are responsible for the maintenance of the inflammatory reaction in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. [J Neuroinflammation. 9: 226.](#)
 18. Cave, N.J. *et al.* (2012) Systemic effects of periodontal disease in cats. [Vet Q. 32: 131-44.](#)
 19. Yuasa, K. *et al.* (2007) Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. [Gene Ther. 14: 1249-60.](#)
 20. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. [Vet Comp Oncol. 12: 29-36.](#)
 21. Heinrich, F. *et al.* (2015) Immunophenotyping of immune cell populations in the raccoon (*Procyon lotor*). [Vet Immunol Immunopathol. 168 \(3-4\): 140-6.](#)
 22. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. [Vet Immunol Immunopathol. 159 \(1-2\): 91-6.](#)
 23. Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. [Vet Immunol Immunopathol. 155 \(3\): 211-7.](#)
 24. Mitchell, L. *et al.* (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. [Vet Immunol Immunopathol. 145 \(3-4\): 597-603.](#)
 25. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. [Immunobiology. 221 \(1\): 12-22.](#)
 26. Izci C *et al.* (2015) Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. [Biotech Histochem. 90 \(3\): 223-30.](#)

27. Ledbetter, E.C. *et al.* (2016) Clinical and immunological assessment of therapeutic immunization with a subunit vaccine for recurrent ocular canine herpesvirus-1 infection in dogs. [Vet Microbiol. 197: 102-10.](#)
28. Lin, S-C. *et al.* (2014) Immune Characterization of Peripheral Blood Mononuclear cells of the Dogs Restored from Innoculation of Canine Transmissible Venereal Tumor Cells. [Tai Vet J. 40 \(04\): 181-90.](#)
29. Herry, V. *et al.* (2017) Local immunization impacts the response of dairy cows to *Escherichia coli* mastitis. [Sci Rep. 7 \(1\): 3441.](#)
30. Gibbons, N. *et al.* (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs. [Vet Immunol Immunopathol. 190: 26-30.](#)
31. Martini, V. *et al.* (2018) Flow cytometry for feline lymphoma: a retrospective study regarding pre-analytical factors possibly affecting the quality of samples. [J Feline Med Surg. 20 \(6\): 494-501.](#)
32. Declue, A.E. *et al.* (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy. [BMC Vet Res. 14 \(1\): 119.](#)
33. DaSilva, A.V.A. *et al.* (2018) Morphophysiological changes in the splenic extracellular matrix of *Leishmania infantum*-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens. [PLoS Negl Trop Dis. 12 \(4\): e0006445.](#)
34. Schmidli, M.R. *et al.* (2018) Inflammatory pattern of the infrapatellar fat pad in dogs with canine cruciate ligament disease. [BMC Vet Res. 14 \(1\): 161.](#)
35. Miranda, L.H.M de M. *et al.* (2018) Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis. [PLoS One. 13 \(11\): e0207644.](#)
36. Maeta, N. *et al.* (2019) Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats. [Open Vet J. 9 \(2\): 147-50.](#)
37. Sato, M. *et al.* (2018) Prognostic significance of hypermethylation of death-associated protein kinase (DAPK) gene CpG island in dogs with high-grade B-cell lymphoma. [Vet Comp Oncol. 16 \(3\): 409-15.](#)
38. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. [BMC Vet Res. 9: 94.](#)
39. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune[®], and Leish-Tec[®] Vaccines against Canine Visceral Leishmaniasis. [Vaccines \(Basel\). 8 \(4\)Nov 17 \[Epub ahead of print\].](#)

Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

12 months from date of despatch

Health And Safety Information

Material Safety Datasheet documentation #10040 available at:

Regulatory

For research purposes only

Related Products

Recommended Secondary Antibodies

Rabbit Anti Mouse IgG (STAR12...)	RPE
Goat Anti Mouse IgG IgA IgM (STAR87...)	HRP
Goat Anti Mouse IgG (STAR76...)	RPE
Goat Anti Mouse IgG (STAR70...)	FITC
Goat Anti Mouse IgG (H/L) (STAR117...)	Alk. Phos. , DyLight®488 , DyLight®550 , DyLight®650 , DyLight®680 , DyLight®800 , FITC , HRP
Goat Anti Mouse IgG (STAR77...)	HRP
Rabbit Anti Mouse IgG (STAR13...)	HRP
Rabbit Anti Mouse IgG (STAR9...)	FITC
Goat Anti Mouse IgG (Fc) (STAR120...)	FITC , HRP

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL \(MCA928\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M365721:200529'

Printed on 30 May 2024